Zida Control Sock

Zida operates at the intersection of medical devices, wearable technology, and neuromodulation, with a focused product for urinary symptoms rather than a broad consumer-wellness wearable. The Zida Control Sock is a prescription device that delivers transcutaneous tibial nerve stimulation, paired with a standalone controller for home use. The product’s differentiators described by the company include knit-in electrodes intended to help with placement, a cotton-blend sock, and a controller that does not depend on Wi-Fi, Bluetooth, or a smartphone. This design emphasizes self-administration and avoids requiring patients to manage a connected app or network-enabled device. Its market position is best characterized as a specialized prescription wearable in at-home urological neuromodulation.

Zida was founded in 2019 and is listed as active, with an employee range of 1–10. The available funding history contains one dated event: non-equity assistance announced on Jan 26, 2026, with Agetech Collaborative from AARP as lead investor. No amount is disclosed, and there is no reported valuation or additional round from which to assess capital growth. This support is a meaningful milestone, but it does not by itself indicate the scale of financing or commercial expansion. Product development centers on the Zida Control Sock, a prescription wearable with embedded electrodes, and its standalone battery-powered control unit. The company’s trajectory therefore appears product-focused, with a 2026 non-equity assistance milestone and a small reported employee range. Further evidence on regulatory progress, distribution, clinical outcomes, and customer uptake would be needed to evaluate its growth rate.